Influenza vaccine - BiondVax

Drug Profile

Influenza vaccine - BiondVax

Alternative Names: BVX-M001; M 001; Multimeric Multi-Epitope Polypeptide Influenza Vaccine; Multimeric-001 Universal Flu Vaccine; Universal Flu Vaccine

Latest Information Update: 01 Dec 2016

Price : $50

At a glance

  • Originator Weizmann Institute of Science
  • Developer BiondVax Pharmaceuticals; National Institutes of Health
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 02 Mar 2017 National Institute of Allergy and Infectious Diseases plans a phase II trial for Influenza virus infections in USA (NCT03058692)
  • 29 Nov 2016 Preliminary adverse events data from a phase IIb trial in Influenza virus infections released by BiondVax
  • 10 Aug 2016 Phase-II clinical trials in Influenza virus infections (Prevention) in USA before August 2016 (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top